LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin alpha3beta1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer[1][2].
Molecular Weight:
885.88
CAS Number:
[1095009-44-1]
Formula:
C32H43N11O15S2
Target:
Integrin
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
